FDA approves Ozempic (semaglutide) license extension for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease -

FDA approves Ozempic (semaglutide) license extension for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease
Information type: Media and commentaries
Source: BioSpace
Specialities: Cardiovascular system disorders | Diabetes | Stroke
Summary
Approval based on SUSTAIN 6 trial which showed semaglutide significantly reduced risk of occurrence of a composite endpoint consisting of cardiovascular death, non-fatal heart attack and non-fatal stroke; when added to standard of care vs. placebo and standard of care.
UKMi comment

Currently in the UK, semaglutide is licensed for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise; with no specific license for cardiovascular risk reduction in adults with type 2 diabetes and known heart disease.
Related links: